Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Travis Steed | Bank of America | 10 questions · 20% challenging |
| Robbie Marcus | JPMorgan | 10 questions · 10% challenging |
| Vijay Kumar | Evercore ISI | 9 questions · 11% challenging |
| Larry Biegelsen | Wells Fargo | 8 questions · 25% challenging |
| Shagun Singh | RBC Capital Markets | 5 questions · 0% challenging |
| Matt Miksic | Barclays | 5 questions · 0% challenging |
| Joanne Wuensch | Citigroup | 5 questions · 0% challenging |
| Patrick Wood | UBS | 4 questions · 0% challenging |
| Josh Jennings | TD Cowen | 3 questions · 0% challenging |
| Pito Chickering | Deutsche Bank | 3 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Bank of America | 1 analyst | 10 questions · 20% challenging |
| JPMorgan | 1 analyst | 10 questions · 10% challenging |
| Evercore ISI | 1 analyst | 9 questions · 11% challenging |
| Wells Fargo | 1 analyst | 8 questions · 25% challenging |
| UBS | 2 analysts | 7 questions · 0% challenging |
| Citigroup | 1 analyst | 5 questions · 0% challenging |
| RBC Capital Markets | 1 analyst | 5 questions · 0% challenging |
| Barclays | 1 analyst | 5 questions · 0% challenging |
No 8-K events recorded for this window.
Medtronic capped its strongest top-line year in a decade, with Q4 revenue of $9.8 billion up 9.9% reported and 6.6% organic and full-year revenue of $36.4 billion up 5.8% organic; Q4 adjusted EPS was $1.55 and adjusted gross margin expanded 30 basis points to 65.4%. Cardiac Ablation Solutions again led growth, up 78% worldwide with PFA up 145% and an 8-point U.S. share gain, while MedSurg accelerated on 11% acute care and monitoring growth and an early contribution from the Hugo robotic platform. Structural heart was flat as U.S. TAVR softened on the Evolut low-risk data before stabilizing over the prior eight weeks. Management introduced fiscal 2027 guidance for the first time, calling for organic revenue growth of 6.75% to 7.25% and EPS of $5.90 to $6.00, and continued to reshape the portfolio through the MiniMed IPO, the CathWorks close, and roughly $2 billion of M&A and venture investments.
Revenue Growth | Product Launch | Margin | Competitive Dynamics | Guidance Reliability | Innovation & R&D | M&A | Regulation Policy | |
|---|---|---|---|---|---|---|---|---|
| 2025Q2 | 3 | 6 | 4 | 4 | 1 | 2 | 1 | 3 |
| 2025Q3 | 7 | 2 | 4 | 4 | 1 | 1 | 1 | |
| 2025Q4 | 5 | 3 | 5 | 3 | 4 | 1 | 2 | 2 |
| 2026Q1 | 6 | 4 | 2 | 2 | 2 | 3 | 3 | 1 |
| 2026Q2 | 6 | 2 | 2 | 1 | 2 | 2 | 2 | 2 |
| 2026Q3 | 8 | 5 | 2 | 4 | 4 | 4 | 2 | |
| 2026Q4 | 2 | 2 | 3 | 4 | 2 | 1 | 1 | 1 |
| '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | '26Q3 | '26Q4 | |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 3 | 7 | 5 | 6 | 6 | 8 | 2 |
| Product Launch | 6 | 2 | 3 | 4 | 2 | 5 | 2 |
| Margin | 4 | 4 | 5 | 2 | 2 | 2 | 3 |
| Competitive Dynamics | 4 | 4 | 3 | 2 | 1 | 4 | 4 |
| Guidance Reliability | 1 | 1 | 4 | 2 | 2 | 4 | 2 |
| Innovation & R&D | 2 | 1 | 1 | 3 | 2 | 4 | 1 |
| M&A | 1 | 2 | 3 | 2 | 2 | 1 | |
| Regulation Policy | 3 | 1 | 2 | 1 | 2 | 1 |
Calendar quarter Q2 2026Earnings call Jun 3, 2026
FY2026 Q4 in brief
Medtronic capped its strongest top-line year in a decade, with Q4 revenue of $9.8 billion up 9.9% reported and 6.6% organic and full-year revenue of $36.4 billion up 5.8% organic; Q4 adjusted EPS was $1.55 and adjusted gross margin expanded 30 basis points…
Newest quarter is part of Pro ·
Sources. Tellvest earnings-call sentiment score for Medtronic (MDT), FY2026 Q4: 8/10. Scores: Medtronic’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: MDT daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2025 Q2 | $8.40B | +5.2% | $0.99 | +45.6% | 64.9% | 19.0% | 15.1% | $554M |
| FY2025 Q3 | $8.29B | +2.5% | $1.01 | +2.0% | 66.5% | 19.9% | 15.6% | $2.10B |
| FY2025 Q4 | $8.93B | +3.9% | $0.82 | +67.3% | 64.7% | 16.1% | 11.8% | $2.07B |
| FY2026 Q1 | $8.58B | +8.4% | $0.81 | +1.3% | 57.7% | 16.8% | 12.1% | $584M |
| FY2026 Q2 | $8.96B | +6.6% | $1.07 | +8.1% | 60.3% | 18.8% | 15.3% | $457M |
| FY2026 Q3 | $9.02B | +8.8% | $0.89 | -11.9% | 64.9% | 19.7% | 12.7% | $2.30B |
| FY2026 Q4Selected | $9.81B | +9.9% | $0.96 | +17.1% | 75.9% | 19.1% | 12.7% | $2.08B |
| FY2027 Q1 | $9.76B | +13.7% | $1.14 | +40.7% | 65.0% | 18.1% | 15.1% | $1.29B |
| Year | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2023 | $31.23B | -1.4% | $2.82 | -24.4% | 65.7% | 17.6% | 12.0% | $4.58B |
| FY2024 | $32.36B | +3.6% | $2.75 | -2.5% | 65.3% | 15.9% | 11.4% | $5.20B |
| FY2025 | $33.54B | +3.6% | $3.62 | +31.6% | 65.3% | 17.8% | 13.9% | $5.18B |
| FY2026Selected | $36.36B | +8.4% | $3.73 | +3.0% | 65.0% | 18.6% | 13.2% | $5.43B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
GAAP revenue YoY +9.86% → base 7. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
What MDT and other companies said about each other on FY2026 Q4 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“targeted external investment in TAVR, including Anteris”
Medtronic made a targeted external investment in TAVR including Anteris, signaling Medtronic's continued interest in the transcatheter aortic valve space.
“We entered into a distribution agreement with Merit Medical for ViaVerte”
Medtronic signed a distribution agreement with Merit Medical for the FDA-cleared ViaVerte chronic vertebrogenic back-pain solution, a channel win for Merit Medical's product.
“We announced plans to acquire Scientia and SPR Therapeutics”
Medtronic plans to acquire SPR Therapeutics to build out its peripheral-nerve-stimulation chronic pain management portfolio.
“We announced plans to acquire Scientia and SPR Therapeutics”
Medtronic plans to acquire Scientia to expand its neurovascular platform with differentiated stroke guidewire technology.
“we closed on the CathWorks transaction.”
Medtronic closed its acquisition of CathWorks, whose AI-based FFRangio system targets the ~$1B wire-based FFR segment, adding non-invasive coronary decision technology to Medtronic's portfolio.
“160 basis points from the MiniMed Blackstone payment”
Medtronic's operating margin carried a 160bp impact from a MiniMed-related Blackstone milestone payment, reflecting Blackstone's life-sciences financing arrangement tied to Medtronic's diabetes unit.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
MDT Medtronic | 8 | +9.9% | |
| ABT Abbott Laboratories | Newest quarter — available with Pro | Newest quarter — available with Pro | |
| ALGN Align Technology | Newest quarter — available with Pro | Newest quarter — available with Pro | |
| BSX Boston Scientific | Newest quarter — available with Pro | Newest quarter — available with Pro | |
| DXCM DexCom | Newest quarter — available with Pro | Newest quarter — available with Pro | |
| EW Edwards Lifesciences | Newest quarter — available with Pro | Newest quarter — available with Pro | |
| PODD Insulet Corporation | Newest quarter — available with Pro | Newest quarter — available with Pro | |
| STE Steris | Newest quarter — available with Pro | Newest quarter — available with Pro | |
| SYK Stryker Corporation | Newest quarter — available with Pro | Newest quarter — available with Pro | |
| ZBH Zimmer Biomet | Newest quarter — available with Pro | Newest quarter — available with Pro |
Newest-quarter details for 9 peers (score, revenue, headline, themes and macro signals) are available with Pro.